Shigellosis
MONDO:0019345Shigellosis is a bacterial infection leading to dysentery and is caused by Shigella, which are small, ubiquitous Gram-negative bacteria belonging to the enterobacteria family. There are four species: S. dysenteriae, S. flexneri, S. boydii and S. sonnei, all of which cause bacillary dysentery and are strictly limited to human hosts.
Also known as: shigellosis, Shigella boydii infectious disease, Shigella flexneri infectious disease, Shigella sonnei infectious disease, Shigella dysentery, flexner's dysentery, japanese dysentery
18 clinical trials for this condition and its sub-types, 14 tagged with Shigellosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New vaccine aims to stop deadly diarrhea in kids
Vaccine Not yet recruitingThis study tests a new vaccine (IP-QSV) designed to protect against four types of Shigella bacteria, which cause severe diarrhea. The trial will include 370 healthy adults, children, and infants in Mali. Researchers will check if the vaccine is safe and triggers a strong immune r…
Phase 1/2 • Sponsor: International Vaccine Institute • Aim: Vaccine
Last updated Jun 27, 2026 14:02 UTC
-
Shigella vaccine immunity checked years later in african kids
Vaccine Not yet recruitingThis study follows up on African children who received an experimental Shigella vaccine in earlier studies. Researchers will take blood samples 1, 2, and 3 years after the last vaccine dose to see how long the immune protection lasts. No new vaccines are given in this study. The …
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 08:08 UTC
-
Can a postbiotic soothe diarrhea in vulnerable kids?
Symptom relief Not yet recruitingThis trial is testing whether a postbiotic supplement called Lactobacillus LB (Lactéol®) is safe for hospitalized children under 18 with weakened immune systems who have diarrhea. Participants receive the supplement twice daily for 14 to 28 days alongside standard rehydration and…
Phase 1/2 • Sponsor: Hospital Infantil de Mexico Federico Gomez • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC